Allergan and MAP Pharmaceuticals Sign Co-Promotion Deal for Acute Migraine Treatment
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 2 (Table of Contents)
Published: 8 Feb-2011
DOI: 10.3833/pdr.v2011.i2.1431 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
In order to strengthen its presence in the migraine market, Allergan has agreed to co-promote MAP Pharmaceuticals’ orally inhaled migraine therapy Levadex™ (dihydroergotamine) to neurologists and pain specialists in the US...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS